Kyle Zingaro

Head of Gene Therapy Process Sciences at UCB

Speaker

Kyle Zingaro joined UCB in 2020 as the Head of Gene Therapy Process Sciences. In this role he has led the establishment of drug substance and drug product process development capabilities for the UCB rAAV gene therapy pipeline. This included acting as the scientific lead for the build of a GMP manufacturing facility and process development labs within UCB and guiding the design and implementation of manufacturing process and process improvements to support the clinical readiness and future commercial demands for the gene therapy pipeline.
Prior to joining UCB, Kyle was the Head of Process Sciences for Thermo Fisher Viral Vector Services where he was the site scientific leader for the Cambridge, Massachusetts commercial manufacturing site and the lead for late-stage development of viral vector therapy products. Here Kyle led a team of process and analytical scientists to help guide and development process development and characterization strategies for novel advanced therapy products to translate these innovative medicines into viable commercial products. Before this role, Kyle led the Upstream Manufacturing Sciences and Technologies team at Brammer Bio at the Cambridge Commercial Manufacturing Site which delivered commercial technology transfers and supported manufacturing operations in the execution of diverse and challenging advanced therapy products. Kyle previously held a number of roles at Alexion Pharmaceuticals supporting upstream and downstream process development including scale down model development for commercial antibody and enzyme replacement products, definition and improvement of manufacturing platform processes, and leadership of cell line development. Kyle holds a Ph.D. in Chemical and Biomolecular Engineering from University of Delaware and a B.S. in Biochemistry from Virginia Tech.